GeoVax Labs (GOVX) Stock Jumps 30%: What Should You Know?

During the last trading session, GeoVax Labs (GOVX) stock was increasing at a sharp speed along with showing active volume and positive change. Such changes could be caused by the latest news from the company that GeoVax has entered into an Assignment and License Agreement with PNP Therapeutics, that grants GeoVax exclusive rights to develop and commercialize GedeptinĀ®, a novel patented product for the treatment of solid tumors. The total market capitalization of the company is 26.45M.GeoVax Labs (GOVX) Stock Jumps 30%: What Should You Know? The License provides exclusive worldwide rights to key intellectual property, including Gedeptin patents, know-how, regulatory filings, clinical materials, and trademarks. The Gedeptin technology was developed with funding support from the National Cancer Institute of the National Institutes of Health. The License also grants GeoVax the right to expand the use of Gedeptin to all human diseases and/or conditions including, but not limited to, other cancers.

Michael Rowels

Weekend Contributor.Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.